The extraordinary success of GLP-1 RAs in T2DM treatment is based on the properties of the incretin hormone GLP-1, which increases the insulin secretory response to an oral glucose load, suppresses glucagon secretion, decelerates gastric emptying, and reduces food seeking [3,29]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.